The goal of this natural history study is to examine the immune responses to the Heplisav-B vaccine in Veterans living with HIV who were non-responders to prior HBV vaccination. A comparison group of HBV vaccine nonresponders without HIV infection will be enrolled to characterize the HIV-associated immune alterations that affect vaccine response. The investigators hypothesize that TLR9-mediated innate immune stimulation with Heplisav will elicit HBV seroprotection despite prior vaccination failures in persons living with HIV, compared to HIV uninfected individuals. Participants eligible for Heplisav-B vaccination will be asked to provide blood samples at multiple timepoints before and after their vaccination.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in B cell functional responses
Timeframe: Day 30
Change in B cell functional responses
Timeframe: Day 60
Change in B cell functional responses
Timeframe: Day 365
Change in B cell phenotypic responses
Timeframe: Day 30
Change in B cell phenotypic responses
Timeframe: Day 60
Change in B cell phenotypic responses
Timeframe: Day 365
Cytokine profile
Timeframe: Day 1